Disease · MONDO_0000402
Trials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 13 of 13
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | Phase 2 | 139 | 2025-03-17 | Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer | CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, GEMCITABINE, IRINOTECAN, NIBROZETONE, PACLITAXEL, PEMETREXED, VINORELBINE | Its record names the disease | ClinicalTrials.gov |
| NCT03896503 | Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | Phase 2 | 104 | 2024-11-13 | Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma | BERZOSERTIB, TOPOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT02769832 | Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | Phase 2 | 32 | 2023-07-21 | Small Cell Lung Cancer (SCLC) | GEMCITABINE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Phase 1/2 | 10 | 2024-01-03 | Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas | DFP-13318, RUCAPARIB | Its record names the disease | ClinicalTrials.gov |
| NCT05566041 | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer | Phase 3 | 292 | Carcinoma, Small Cell Lung | CARBOPLATIN, CISPLATIN, ETOPOSIDE, NIBROZETONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06441344 | Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell | Phase 3 | 136 | SCLC, Maintenance Treatment | CARBOPLATIN, CATEQUENTINIB, CISPLATIN, ETOPOSIDE, TORIPALIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00500422 | Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | Phase 1 | 134 | Solid Tumors | BORTEZOMIB, DOXORUBICIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06464068 | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA | Phase 2 | 66 | Extrapulmonary Small Cell Carcinoma | CARBOPLATIN, CISPLATIN, DURVALUMAB, ETOPOSIDE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT05760053 | Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma | Phase 2 | 33 | Toripalimab, First-line Treatment | CARBOPLATIN, CISPLATIN, ETOPOSIDE, TORIPALIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06816394 | Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) | Phase 2 | 32 | Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | TARLATAMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03699956 | RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer | Phase 3 | 18 | Carcinoma, Small Cell Lung | CARBOPLATIN, CISPLATIN, ETOPOSIDE, NIBROZETONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02881125 | Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma | Phase 1 | 2 | Small Cell Carcinoma | NORTRIPTYLINE HYDROCHLORIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | Phase 1/2 | 0 | Small Cell Lung Cancer (SCLC), Neuroendocrine (NE) Tumors, Large Cell Neuroendocrine (NE) Tumors | TOPOTECAN | Open Targets' reading of its record | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000402/trials